Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Cancer Gene Ther ; 15(8): 535-42, 2008 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-18421310

RESUMO

Ad-PPE-Fas-c is an adenovector that expresses Fas-c under the control of the modified pre-proendothelin-1 (PPE-1) promoter. Fas-c is a chimeric death receptor containing the extracellular portion of tumour necrosis factor 1 receptor (TNFR1) and the transmembrane and intracellular portion of Fas. We recently demonstrated that Ad-PPE-Fas-c induced Fas-receptor-mediated endothelial cell apoptosis. Previously, doxorubicin was shown to enhance Fas-receptor clustering and the induction of its cascade. Therefore, the goal of this work was to test whether doxorubicin augments the capacity of Ad-PPE-Fas-c to induce endothelial cell apoptosis and to elucidate whether either the death-receptor-mediated apoptotic cascade or the mitochondria-associated apoptotic cascade is involved in the combined treatment effect. We found that a combined treatment of Ad-PPE-Fas-c and doxorubicin synergistically induced a reduction in endothelial cell viability and apoptosis. z-IETD-FMK, a caspase-8 inhibitor, and z-LEHD-FMK, a caspase-9 inhibitor, significantly decreased apoptosis induced by the combined treatment. Systemically administered combined therapy significantly reduced the lung metastases burden (70%) in mice as compared to each treatment alone. Thus, a combined treatment of Ad-PPE-Fas-c gene therapy and chemotherapy may be effective in the treatment of metastatic diseases and both the Fas cascade and the mitochondria-associated cascade are essential for this effect.


Assuntos
Apoptose/efeitos dos fármacos , Caspase 8/metabolismo , Caspase 9/metabolismo , Doxorrubicina/administração & dosagem , Endotélio Vascular/efeitos dos fármacos , Terapia Genética , Metástase Neoplásica/prevenção & controle , Neovascularização Patológica/prevenção & controle , Adenoviridae/genética , Animais , Bovinos , Células Cultivadas , Endotélio Vascular/citologia , Vetores Genéticos , Camundongos , Camundongos Endogâmicos C57BL
2.
Isr J Med Sci ; 31(8): 492-6, 1995 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-7635699

RESUMO

In vitro fertilization (IVF) has become a routine tool in the arsenal of infertility treatments. Assisted reproductive techniques are expensive, as reflected by the current "take home baby" rate of about 15% per cycle, implying the need for repeated attempts until success is achieved. Israel, today is facing a major change in its health care system, including the necessity to define a national package of health care benefits. The issue of infertility and whether its treatment should be part of the "health basket" is in dispute. Therefore an exact cost analysis of IVF is important. Since the cost of an IVF cycle varies dramatically between countries, we sought an exact breakdown of the different components of the costs involved in an IVF cycle and in achieving an IVF child in Israel. The key question is not how much we spend on IVF cycles but what is the cost of a successful outcome, i.e., a healthy child. This study intends to answer this question, and to give the policy makers, at various levels of the health care system, a crucial tool for their decision-making process. The cost analysis includes direct and indirect costs. The direct costs are divided into fixed costs (labor, equipment, maintenance, depreciation, and overhead) and variable costs (laboratory tests, chemicals, disposable supplies, medications, and loss of working days by the couples). The indirect costs are the costs of premature IVF babies, hospitalization of the IVF pregnant women in a high risk unit, and the cost of complications of the procedure. According to our economic analysis, an IVF cycle in Israel costs $2,560, of which fixed costs are about 50%. The cost of a "take home baby" is $19,267, including direct and indirect costs.


Assuntos
Fertilização in vitro/economia , Custos e Análise de Custo , Feminino , Humanos , Israel , Gravidez , Resultado da Gravidez/economia
3.
J Consult Clin Psychol ; 57(2): 287-93, 1989 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-2708617

RESUMO

The present study explored the differences between male and female Holocaust survivors (n = 34) and controls (n = 34) who were similar to the survivors but had not been victims of the Holocaust. Half of the respondents were from the city and the other half were from the Kibbutz. The main dependent measures included the CAQ, the TSCS, and a specially designed Centrality of Family scale. Survivors were worse off psychologically than comparison individuals on the quality of emotional life, on emotional expression, and on the quality of interpersonal relations. Also, survivors assigned relatively greater value to their postwar families. City survivors seem to be worse off than Kibbutz survivors, and male survivors from the city had the lowest scores on several key subscales. These data were corroborated and extended by a content analysis of an open-ended interview conducted after the objective measures had been completed. The findings and their implications for understanding the effects of massive traumatization over individuals' life cycles are discussed.


Assuntos
Campos de Concentração , Judeus/psicologia , Prisões , Meio Social , Transtornos de Estresse Pós-Traumáticos/psicologia , Sobrevida , Adaptação Psicológica , Idoso , Feminino , Seguimentos , Humanos , Israel , Masculino , Pessoa de Meia-Idade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA